nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—multiple sclerosis	0.358	1	CbGaD
Thalidomide—CYP2E1—Fingolimod—multiple sclerosis	0.0657	0.222	CbGbCtD
Thalidomide—PTGS2—Triamcinolone—multiple sclerosis	0.0492	0.166	CbGbCtD
Thalidomide—PTGS2—Betamethasone—multiple sclerosis	0.0422	0.142	CbGbCtD
Thalidomide—CYP2E1—Mitoxantrone—multiple sclerosis	0.0309	0.104	CbGbCtD
Thalidomide—PTGS2—Dexamethasone—multiple sclerosis	0.0245	0.0829	CbGbCtD
Thalidomide—CYP1A1—Dexamethasone—multiple sclerosis	0.0207	0.07	CbGbCtD
Thalidomide—CYP2C19—Prednisone—multiple sclerosis	0.0161	0.0543	CbGbCtD
Thalidomide—CYP2E1—Dexamethasone—multiple sclerosis	0.016	0.0541	CbGbCtD
Thalidomide—CYP3A5—Dexamethasone—multiple sclerosis	0.0124	0.042	CbGbCtD
Thalidomide—CYP2C19—Dexamethasone—multiple sclerosis	0.01	0.0339	CbGbCtD
Thalidomide—CYP2C9—Dexamethasone—multiple sclerosis	0.00834	0.0282	CbGbCtD
Thalidomide—Pomalidomide—TNF—multiple sclerosis	0.00202	1	CrCbGaD
Thalidomide—PTGS2—leg—multiple sclerosis	0.0012	0.0803	CbGeAlD
Thalidomide—CRBN—retina—multiple sclerosis	0.000989	0.0664	CbGeAlD
Thalidomide—FGFR2—brainstem—multiple sclerosis	0.000918	0.0616	CbGeAlD
Thalidomide—CRBN—medulla oblongata—multiple sclerosis	0.000715	0.048	CbGeAlD
Thalidomide—CRBN—midbrain—multiple sclerosis	0.000653	0.0438	CbGeAlD
Thalidomide—NFKB1—nervous system—multiple sclerosis	0.000641	0.043	CbGeAlD
Thalidomide—CRBN—spinal cord—multiple sclerosis	0.000637	0.0428	CbGeAlD
Thalidomide—NFKB1—central nervous system—multiple sclerosis	0.000617	0.0414	CbGeAlD
Thalidomide—NFKB1—cerebellum—multiple sclerosis	0.000603	0.0405	CbGeAlD
Thalidomide—FGFR2—spinal cord—multiple sclerosis	0.000571	0.0383	CbGeAlD
Thalidomide—CRBN—nervous system—multiple sclerosis	0.000537	0.036	CbGeAlD
Thalidomide—CRBN—central nervous system—multiple sclerosis	0.000517	0.0347	CbGeAlD
Thalidomide—CRBN—cerebellum—multiple sclerosis	0.000505	0.0339	CbGeAlD
Thalidomide—NFKB1—brain—multiple sclerosis	0.00049	0.0329	CbGeAlD
Thalidomide—FGFR2—nervous system—multiple sclerosis	0.000481	0.0323	CbGeAlD
Thalidomide—FGFR2—central nervous system—multiple sclerosis	0.000463	0.0311	CbGeAlD
Thalidomide—FGFR2—cerebellum—multiple sclerosis	0.000453	0.0304	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000451	0.159	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000444	0.156	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000444	0.156	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000434	0.153	CbGdCrCtD
Thalidomide—CRBN—brain—multiple sclerosis	0.00041	0.0275	CbGeAlD
Thalidomide—FGFR2—brain—multiple sclerosis	0.000368	0.0247	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000272	0.0958	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000268	0.0943	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000268	0.0943	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000262	0.0921	CbGdCrCtD
Thalidomide—CYP2E1—medulla oblongata—multiple sclerosis	0.000211	0.0142	CbGeAlD
Thalidomide—PTGS2—medulla oblongata—multiple sclerosis	0.000195	0.0131	CbGeAlD
Thalidomide—CYP2E1—spinal cord—multiple sclerosis	0.000188	0.0126	CbGeAlD
Thalidomide—PTGS1—spinal cord—multiple sclerosis	0.000182	0.0122	CbGeAlD
Thalidomide—PTGS2—midbrain—multiple sclerosis	0.000178	0.0119	CbGeAlD
Thalidomide—CYP1A1—nervous system—multiple sclerosis	0.000174	0.0117	CbGeAlD
Thalidomide—PTGS2—spinal cord—multiple sclerosis	0.000174	0.0116	CbGeAlD
Thalidomide—CYP1A1—central nervous system—multiple sclerosis	0.000168	0.0113	CbGeAlD
Thalidomide—CYP2E1—nervous system—multiple sclerosis	0.000159	0.0107	CbGeAlD
Thalidomide—PTGS1—nervous system—multiple sclerosis	0.000153	0.0103	CbGeAlD
Thalidomide—CYP2E1—central nervous system—multiple sclerosis	0.000153	0.0103	CbGeAlD
Thalidomide—CYP2E1—cerebellum—multiple sclerosis	0.000149	0.01	CbGeAlD
Thalidomide—PTGS1—central nervous system—multiple sclerosis	0.000147	0.00988	CbGeAlD
Thalidomide—PTGS2—nervous system—multiple sclerosis	0.000146	0.00981	CbGeAlD
Thalidomide—PTGS2—central nervous system—multiple sclerosis	0.000141	0.00945	CbGeAlD
Thalidomide—PTGS2—cerebellum—multiple sclerosis	0.000138	0.00923	CbGeAlD
Thalidomide—CYP1A1—brain—multiple sclerosis	0.000133	0.00893	CbGeAlD
Thalidomide—CYP2E1—brain—multiple sclerosis	0.000121	0.00815	CbGeAlD
Thalidomide—PTGS1—brain—multiple sclerosis	0.000117	0.00785	CbGeAlD
Thalidomide—PTGS2—brain—multiple sclerosis	0.000112	0.0075	CbGeAlD
Thalidomide—Loss of consciousness—Betamethasone—multiple sclerosis	6.4e-05	0.000361	CcSEcCtD
Thalidomide—Epistaxis—Methotrexate—multiple sclerosis	6.39e-05	0.000361	CcSEcCtD
Thalidomide—Hypersensitivity—Mitoxantrone—multiple sclerosis	6.39e-05	0.00036	CcSEcCtD
Thalidomide—Paraesthesia—Prednisolone—multiple sclerosis	6.39e-05	0.00036	CcSEcCtD
Thalidomide—Tachycardia—Triamcinolone—multiple sclerosis	6.39e-05	0.00036	CcSEcCtD
Thalidomide—Mental disorder—Prednisone—multiple sclerosis	6.38e-05	0.00036	CcSEcCtD
Thalidomide—Nausea—Azathioprine—multiple sclerosis	6.38e-05	0.000359	CcSEcCtD
Thalidomide—Tachycardia—Methylprednisolone—multiple sclerosis	6.38e-05	0.000359	CcSEcCtD
Thalidomide—Skin disorder—Methylprednisolone—multiple sclerosis	6.34e-05	0.000358	CcSEcCtD
Thalidomide—Malnutrition—Prednisone—multiple sclerosis	6.34e-05	0.000357	CcSEcCtD
Thalidomide—Hyperhidrosis—Triamcinolone—multiple sclerosis	6.33e-05	0.000357	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—multiple sclerosis	6.33e-05	0.000357	CcSEcCtD
Thalidomide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	6.31e-05	0.000356	CcSEcCtD
Thalidomide—Convulsion—Dexamethasone—multiple sclerosis	6.31e-05	0.000356	CcSEcCtD
Thalidomide—Convulsion—Betamethasone—multiple sclerosis	6.31e-05	0.000356	CcSEcCtD
Thalidomide—Hypertension—Betamethasone—multiple sclerosis	6.28e-05	0.000354	CcSEcCtD
Thalidomide—Hypertension—Dexamethasone—multiple sclerosis	6.28e-05	0.000354	CcSEcCtD
Thalidomide—Asthenia—Mitoxantrone—multiple sclerosis	6.23e-05	0.000351	CcSEcCtD
Thalidomide—Myalgia—Dexamethasone—multiple sclerosis	6.2e-05	0.000349	CcSEcCtD
Thalidomide—Myalgia—Betamethasone—multiple sclerosis	6.2e-05	0.000349	CcSEcCtD
Thalidomide—Anxiety—Dexamethasone—multiple sclerosis	6.18e-05	0.000348	CcSEcCtD
Thalidomide—Anxiety—Betamethasone—multiple sclerosis	6.18e-05	0.000348	CcSEcCtD
Thalidomide—Discomfort—Betamethasone—multiple sclerosis	6.12e-05	0.000345	CcSEcCtD
Thalidomide—Discomfort—Dexamethasone—multiple sclerosis	6.12e-05	0.000345	CcSEcCtD
Thalidomide—Hypotension—Methylprednisolone—multiple sclerosis	6.1e-05	0.000344	CcSEcCtD
Thalidomide—Pain—Prednisolone—multiple sclerosis	6.09e-05	0.000343	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—multiple sclerosis	6.09e-05	0.000343	CcSEcCtD
Thalidomide—Pharyngitis—Methotrexate—multiple sclerosis	6.04e-05	0.000341	CcSEcCtD
Thalidomide—Urinary tract disorder—Methotrexate—multiple sclerosis	6.01e-05	0.000339	CcSEcCtD
Thalidomide—Vision blurred—Prednisone—multiple sclerosis	5.97e-05	0.000337	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—multiple sclerosis	5.97e-05	0.000336	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	5.96e-05	0.000336	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	5.95e-05	0.000336	CcSEcCtD
Thalidomide—Oedema—Dexamethasone—multiple sclerosis	5.94e-05	0.000335	CcSEcCtD
Thalidomide—Oedema—Betamethasone—multiple sclerosis	5.94e-05	0.000335	CcSEcCtD
Thalidomide—Diarrhoea—Mitoxantrone—multiple sclerosis	5.94e-05	0.000335	CcSEcCtD
Thalidomide—Insomnia—Triamcinolone—multiple sclerosis	5.92e-05	0.000334	CcSEcCtD
Thalidomide—Insomnia—Methylprednisolone—multiple sclerosis	5.91e-05	0.000333	CcSEcCtD
Thalidomide—Infection—Betamethasone—multiple sclerosis	5.9e-05	0.000333	CcSEcCtD
Thalidomide—Infection—Dexamethasone—multiple sclerosis	5.9e-05	0.000333	CcSEcCtD
Thalidomide—Ill-defined disorder—Prednisone—multiple sclerosis	5.88e-05	0.000332	CcSEcCtD
Thalidomide—Paraesthesia—Triamcinolone—multiple sclerosis	5.88e-05	0.000331	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisolone—multiple sclerosis	5.87e-05	0.000331	CcSEcCtD
Thalidomide—Paraesthesia—Methylprednisolone—multiple sclerosis	5.87e-05	0.000331	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—multiple sclerosis	5.86e-05	0.000331	CcSEcCtD
Thalidomide—Anaemia—Prednisone—multiple sclerosis	5.86e-05	0.00033	CcSEcCtD
Thalidomide—Shock—Betamethasone—multiple sclerosis	5.84e-05	0.00033	CcSEcCtD
Thalidomide—Shock—Dexamethasone—multiple sclerosis	5.84e-05	0.00033	CcSEcCtD
Thalidomide—Dyspnoea—Triamcinolone—multiple sclerosis	5.84e-05	0.000329	CcSEcCtD
Thalidomide—Nervous system disorder—Betamethasone—multiple sclerosis	5.83e-05	0.000328	CcSEcCtD
Thalidomide—Nervous system disorder—Dexamethasone—multiple sclerosis	5.83e-05	0.000328	CcSEcCtD
Thalidomide—Agitation—Prednisone—multiple sclerosis	5.82e-05	0.000328	CcSEcCtD
Thalidomide—Thrombocytopenia—Betamethasone—multiple sclerosis	5.82e-05	0.000328	CcSEcCtD
Thalidomide—Thrombocytopenia—Dexamethasone—multiple sclerosis	5.82e-05	0.000328	CcSEcCtD
Thalidomide—Tachycardia—Betamethasone—multiple sclerosis	5.8e-05	0.000327	CcSEcCtD
Thalidomide—Tachycardia—Dexamethasone—multiple sclerosis	5.8e-05	0.000327	CcSEcCtD
Thalidomide—Angioedema—Prednisone—multiple sclerosis	5.79e-05	0.000327	CcSEcCtD
Thalidomide—Dyspepsia—Triamcinolone—multiple sclerosis	5.76e-05	0.000325	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—multiple sclerosis	5.75e-05	0.000324	CcSEcCtD
Thalidomide—Dyspepsia—Methylprednisolone—multiple sclerosis	5.75e-05	0.000324	CcSEcCtD
Thalidomide—Hyperhidrosis—Dexamethasone—multiple sclerosis	5.74e-05	0.000324	CcSEcCtD
Thalidomide—Hyperhidrosis—Betamethasone—multiple sclerosis	5.74e-05	0.000324	CcSEcCtD
Thalidomide—Malaise—Prednisone—multiple sclerosis	5.72e-05	0.000322	CcSEcCtD
Thalidomide—Vertigo—Prednisone—multiple sclerosis	5.69e-05	0.000321	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—multiple sclerosis	5.69e-05	0.000321	CcSEcCtD
Thalidomide—Syncope—Prednisone—multiple sclerosis	5.68e-05	0.000321	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—multiple sclerosis	5.67e-05	0.00032	CcSEcCtD
Thalidomide—Anorexia—Betamethasone—multiple sclerosis	5.66e-05	0.000319	CcSEcCtD
Thalidomide—Anorexia—Dexamethasone—multiple sclerosis	5.66e-05	0.000319	CcSEcCtD
Thalidomide—Urticaria—Prednisolone—multiple sclerosis	5.66e-05	0.000319	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—multiple sclerosis	5.65e-05	0.000318	CcSEcCtD
Thalidomide—Fatigue—Triamcinolone—multiple sclerosis	5.64e-05	0.000318	CcSEcCtD
Thalidomide—Fatigue—Methylprednisolone—multiple sclerosis	5.63e-05	0.000318	CcSEcCtD
Thalidomide—Pain—Triamcinolone—multiple sclerosis	5.6e-05	0.000316	CcSEcCtD
Thalidomide—Loss of consciousness—Prednisone—multiple sclerosis	5.57e-05	0.000314	CcSEcCtD
Thalidomide—Hypotension—Betamethasone—multiple sclerosis	5.55e-05	0.000313	CcSEcCtD
Thalidomide—Hypotension—Dexamethasone—multiple sclerosis	5.55e-05	0.000313	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—multiple sclerosis	5.52e-05	0.000311	CcSEcCtD
Thalidomide—Vomiting—Mitoxantrone—multiple sclerosis	5.52e-05	0.000311	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—multiple sclerosis	5.5e-05	0.00031	CcSEcCtD
Thalidomide—Convulsion—Prednisone—multiple sclerosis	5.49e-05	0.00031	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—multiple sclerosis	5.48e-05	0.000309	CcSEcCtD
Thalidomide—Hypertension—Prednisone—multiple sclerosis	5.47e-05	0.000309	CcSEcCtD
Thalidomide—Rash—Mitoxantrone—multiple sclerosis	5.47e-05	0.000308	CcSEcCtD
Thalidomide—Dermatitis—Mitoxantrone—multiple sclerosis	5.47e-05	0.000308	CcSEcCtD
Thalidomide—Chills—Methotrexate—multiple sclerosis	5.46e-05	0.000308	CcSEcCtD
Thalidomide—Headache—Mitoxantrone—multiple sclerosis	5.44e-05	0.000307	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	5.41e-05	0.000305	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	5.41e-05	0.000305	CcSEcCtD
Thalidomide—Myalgia—Prednisone—multiple sclerosis	5.4e-05	0.000304	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—multiple sclerosis	5.4e-05	0.000304	CcSEcCtD
Thalidomide—Feeling abnormal—Triamcinolone—multiple sclerosis	5.39e-05	0.000304	CcSEcCtD
Thalidomide—Feeling abnormal—Methylprednisolone—multiple sclerosis	5.38e-05	0.000304	CcSEcCtD
Thalidomide—Anxiety—Prednisone—multiple sclerosis	5.38e-05	0.000303	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—multiple sclerosis	5.38e-05	0.000303	CcSEcCtD
Thalidomide—Insomnia—Dexamethasone—multiple sclerosis	5.37e-05	0.000303	CcSEcCtD
Thalidomide—Insomnia—Betamethasone—multiple sclerosis	5.37e-05	0.000303	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	5.36e-05	0.000302	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	5.34e-05	0.000301	CcSEcCtD
Thalidomide—Paraesthesia—Betamethasone—multiple sclerosis	5.33e-05	0.000301	CcSEcCtD
Thalidomide—Paraesthesia—Dexamethasone—multiple sclerosis	5.33e-05	0.000301	CcSEcCtD
Thalidomide—Discomfort—Prednisone—multiple sclerosis	5.33e-05	0.000301	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—multiple sclerosis	5.33e-05	0.000301	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—multiple sclerosis	5.3e-05	0.000299	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisolone—multiple sclerosis	5.24e-05	0.000296	CcSEcCtD
Thalidomide—Dyspepsia—Dexamethasone—multiple sclerosis	5.23e-05	0.000295	CcSEcCtD
Thalidomide—Dyspepsia—Betamethasone—multiple sclerosis	5.23e-05	0.000295	CcSEcCtD
Thalidomide—Urticaria—Triamcinolone—multiple sclerosis	5.2e-05	0.000293	CcSEcCtD
Thalidomide—Urticaria—Methylprednisolone—multiple sclerosis	5.19e-05	0.000293	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—multiple sclerosis	5.19e-05	0.000292	CcSEcCtD
Thalidomide—Body temperature increased—Triamcinolone—multiple sclerosis	5.18e-05	0.000292	CcSEcCtD
Thalidomide—Oedema—Prednisone—multiple sclerosis	5.17e-05	0.000292	CcSEcCtD
Thalidomide—Abdominal pain—Methylprednisolone—multiple sclerosis	5.16e-05	0.000291	CcSEcCtD
Thalidomide—Decreased appetite—Betamethasone—multiple sclerosis	5.16e-05	0.000291	CcSEcCtD
Thalidomide—Decreased appetite—Dexamethasone—multiple sclerosis	5.16e-05	0.000291	CcSEcCtD
Thalidomide—Nausea—Mitoxantrone—multiple sclerosis	5.15e-05	0.000291	CcSEcCtD
Thalidomide—Infection—Prednisone—multiple sclerosis	5.14e-05	0.00029	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	5.13e-05	0.000289	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	5.13e-05	0.000289	CcSEcCtD
Thalidomide—Back pain—Methotrexate—multiple sclerosis	5.12e-05	0.000289	CcSEcCtD
Thalidomide—Fatigue—Dexamethasone—multiple sclerosis	5.12e-05	0.000289	CcSEcCtD
Thalidomide—Fatigue—Betamethasone—multiple sclerosis	5.12e-05	0.000289	CcSEcCtD
Thalidomide—Shock—Prednisone—multiple sclerosis	5.09e-05	0.000287	CcSEcCtD
Thalidomide—Pain—Betamethasone—multiple sclerosis	5.08e-05	0.000286	CcSEcCtD
Thalidomide—Pain—Dexamethasone—multiple sclerosis	5.08e-05	0.000286	CcSEcCtD
Thalidomide—Nervous system disorder—Prednisone—multiple sclerosis	5.07e-05	0.000286	CcSEcCtD
Thalidomide—Tachycardia—Prednisone—multiple sclerosis	5.05e-05	0.000285	CcSEcCtD
Thalidomide—Skin disorder—Prednisone—multiple sclerosis	5.02e-05	0.000283	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisone—multiple sclerosis	5e-05	0.000282	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—multiple sclerosis	4.99e-05	0.000281	CcSEcCtD
Thalidomide—Anorexia—Prednisone—multiple sclerosis	4.93e-05	0.000278	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—multiple sclerosis	4.91e-05	0.000277	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—multiple sclerosis	4.9e-05	0.000276	CcSEcCtD
Thalidomide—Feeling abnormal—Dexamethasone—multiple sclerosis	4.89e-05	0.000276	CcSEcCtD
Thalidomide—Feeling abnormal—Betamethasone—multiple sclerosis	4.89e-05	0.000276	CcSEcCtD
Thalidomide—Gastrointestinal pain—Betamethasone—multiple sclerosis	4.86e-05	0.000274	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	4.86e-05	0.000274	CcSEcCtD
Thalidomide—Hypersensitivity—Triamcinolone—multiple sclerosis	4.82e-05	0.000272	CcSEcCtD
Thalidomide—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.81e-05	0.000271	CcSEcCtD
Thalidomide—Malaise—Methotrexate—multiple sclerosis	4.78e-05	0.000269	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—multiple sclerosis	4.76e-05	0.000268	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—multiple sclerosis	4.74e-05	0.000267	CcSEcCtD
Thalidomide—Urticaria—Betamethasone—multiple sclerosis	4.72e-05	0.000266	CcSEcCtD
Thalidomide—Urticaria—Dexamethasone—multiple sclerosis	4.72e-05	0.000266	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	4.71e-05	0.000266	CcSEcCtD
Thalidomide—Dizziness—Prednisolone—multiple sclerosis	4.71e-05	0.000265	CcSEcCtD
Thalidomide—Asthenia—Triamcinolone—multiple sclerosis	4.7e-05	0.000265	CcSEcCtD
Thalidomide—Body temperature increased—Dexamethasone—multiple sclerosis	4.7e-05	0.000265	CcSEcCtD
Thalidomide—Body temperature increased—Betamethasone—multiple sclerosis	4.7e-05	0.000265	CcSEcCtD
Thalidomide—Abdominal pain—Betamethasone—multiple sclerosis	4.7e-05	0.000265	CcSEcCtD
Thalidomide—Abdominal pain—Dexamethasone—multiple sclerosis	4.7e-05	0.000265	CcSEcCtD
Thalidomide—Asthenia—Methylprednisolone—multiple sclerosis	4.69e-05	0.000264	CcSEcCtD
Thalidomide—Insomnia—Prednisone—multiple sclerosis	4.68e-05	0.000264	CcSEcCtD
Thalidomide—Paraesthesia—Prednisone—multiple sclerosis	4.65e-05	0.000262	CcSEcCtD
Thalidomide—Pruritus—Triamcinolone—multiple sclerosis	4.63e-05	0.000261	CcSEcCtD
Thalidomide—Cough—Methotrexate—multiple sclerosis	4.62e-05	0.000261	CcSEcCtD
Thalidomide—Pruritus—Methylprednisolone—multiple sclerosis	4.62e-05	0.000261	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—multiple sclerosis	4.59e-05	0.000259	CcSEcCtD
Thalidomide—Dyspepsia—Prednisone—multiple sclerosis	4.55e-05	0.000257	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—multiple sclerosis	4.51e-05	0.000254	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—multiple sclerosis	4.51e-05	0.000254	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—multiple sclerosis	4.51e-05	0.000254	CcSEcCtD
Thalidomide—Decreased appetite—Prednisone—multiple sclerosis	4.5e-05	0.000254	CcSEcCtD
Thalidomide—Rash—Prednisolone—multiple sclerosis	4.49e-05	0.000253	CcSEcCtD
Thalidomide—Dermatitis—Prednisolone—multiple sclerosis	4.48e-05	0.000253	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	4.48e-05	0.000253	CcSEcCtD
Thalidomide—Diarrhoea—Methylprednisolone—multiple sclerosis	4.47e-05	0.000252	CcSEcCtD
Thalidomide—Fatigue—Prednisone—multiple sclerosis	4.46e-05	0.000251	CcSEcCtD
Thalidomide—Headache—Prednisolone—multiple sclerosis	4.46e-05	0.000251	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—multiple sclerosis	4.46e-05	0.000251	CcSEcCtD
Thalidomide—Constipation—Prednisone—multiple sclerosis	4.42e-05	0.000249	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—multiple sclerosis	4.36e-05	0.000246	CcSEcCtD
Thalidomide—Dizziness—Triamcinolone—multiple sclerosis	4.33e-05	0.000244	CcSEcCtD
Thalidomide—Dizziness—Methylprednisolone—multiple sclerosis	4.32e-05	0.000244	CcSEcCtD
Thalidomide—Infection—Methotrexate—multiple sclerosis	4.3e-05	0.000242	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisone—multiple sclerosis	4.26e-05	0.00024	CcSEcCtD
Thalidomide—Asthenia—Dexamethasone—multiple sclerosis	4.26e-05	0.00024	CcSEcCtD
Thalidomide—Asthenia—Betamethasone—multiple sclerosis	4.26e-05	0.00024	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—multiple sclerosis	4.24e-05	0.000239	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—multiple sclerosis	4.23e-05	0.000239	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—multiple sclerosis	4.23e-05	0.000239	CcSEcCtD
Thalidomide—Nausea—Prednisolone—multiple sclerosis	4.23e-05	0.000238	CcSEcCtD
Thalidomide—Pruritus—Betamethasone—multiple sclerosis	4.2e-05	0.000237	CcSEcCtD
Thalidomide—Pruritus—Dexamethasone—multiple sclerosis	4.2e-05	0.000237	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—multiple sclerosis	4.2e-05	0.000237	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—multiple sclerosis	4.18e-05	0.000236	CcSEcCtD
Thalidomide—Vomiting—Triamcinolone—multiple sclerosis	4.16e-05	0.000235	CcSEcCtD
Thalidomide—Vomiting—Methylprednisolone—multiple sclerosis	4.15e-05	0.000234	CcSEcCtD
Thalidomide—Rash—Triamcinolone—multiple sclerosis	4.13e-05	0.000233	CcSEcCtD
Thalidomide—Dermatitis—Triamcinolone—multiple sclerosis	4.12e-05	0.000233	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—multiple sclerosis	4.12e-05	0.000232	CcSEcCtD
Thalidomide—Rash—Methylprednisolone—multiple sclerosis	4.12e-05	0.000232	CcSEcCtD
Thalidomide—Dermatitis—Methylprednisolone—multiple sclerosis	4.11e-05	0.000232	CcSEcCtD
Thalidomide—Urticaria—Prednisone—multiple sclerosis	4.11e-05	0.000232	CcSEcCtD
Thalidomide—Headache—Triamcinolone—multiple sclerosis	4.1e-05	0.000231	CcSEcCtD
Thalidomide—Headache—Methylprednisolone—multiple sclerosis	4.09e-05	0.000231	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—multiple sclerosis	4.09e-05	0.000231	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—multiple sclerosis	4.09e-05	0.000231	CcSEcCtD
Thalidomide—Diarrhoea—Dexamethasone—multiple sclerosis	4.06e-05	0.000229	CcSEcCtD
Thalidomide—Diarrhoea—Betamethasone—multiple sclerosis	4.06e-05	0.000229	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—multiple sclerosis	4.04e-05	0.000228	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	3.94e-05	0.000222	CcSEcCtD
Thalidomide—Dizziness—Betamethasone—multiple sclerosis	3.93e-05	0.000221	CcSEcCtD
Thalidomide—Dizziness—Dexamethasone—multiple sclerosis	3.93e-05	0.000221	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—multiple sclerosis	3.91e-05	0.00022	CcSEcCtD
Thalidomide—Nausea—Triamcinolone—multiple sclerosis	3.89e-05	0.000219	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—multiple sclerosis	3.88e-05	0.000219	CcSEcCtD
Thalidomide—Nausea—Methylprednisolone—multiple sclerosis	3.88e-05	0.000219	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—multiple sclerosis	3.85e-05	0.000217	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—multiple sclerosis	3.84e-05	0.000217	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—multiple sclerosis	3.81e-05	0.000215	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—multiple sclerosis	3.81e-05	0.000215	CcSEcCtD
Thalidomide—Vomiting—Dexamethasone—multiple sclerosis	3.78e-05	0.000213	CcSEcCtD
Thalidomide—Vomiting—Betamethasone—multiple sclerosis	3.78e-05	0.000213	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—multiple sclerosis	3.76e-05	0.000212	CcSEcCtD
Thalidomide—Rash—Dexamethasone—multiple sclerosis	3.75e-05	0.000211	CcSEcCtD
Thalidomide—Rash—Betamethasone—multiple sclerosis	3.75e-05	0.000211	CcSEcCtD
Thalidomide—Dermatitis—Betamethasone—multiple sclerosis	3.74e-05	0.000211	CcSEcCtD
Thalidomide—Dermatitis—Dexamethasone—multiple sclerosis	3.74e-05	0.000211	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.73e-05	0.00021	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—multiple sclerosis	3.73e-05	0.00021	CcSEcCtD
Thalidomide—Headache—Betamethasone—multiple sclerosis	3.72e-05	0.00021	CcSEcCtD
Thalidomide—Headache—Dexamethasone—multiple sclerosis	3.72e-05	0.00021	CcSEcCtD
Thalidomide—Asthenia—Prednisone—multiple sclerosis	3.71e-05	0.000209	CcSEcCtD
Thalidomide—Pain—Methotrexate—multiple sclerosis	3.7e-05	0.000208	CcSEcCtD
Thalidomide—Pruritus—Prednisone—multiple sclerosis	3.66e-05	0.000206	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—multiple sclerosis	3.56e-05	0.000201	CcSEcCtD
Thalidomide—Diarrhoea—Prednisone—multiple sclerosis	3.54e-05	0.0002	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—multiple sclerosis	3.54e-05	0.000199	CcSEcCtD
Thalidomide—Nausea—Dexamethasone—multiple sclerosis	3.53e-05	0.000199	CcSEcCtD
Thalidomide—Nausea—Betamethasone—multiple sclerosis	3.53e-05	0.000199	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—multiple sclerosis	3.43e-05	0.000194	CcSEcCtD
Thalidomide—Dizziness—Prednisone—multiple sclerosis	3.42e-05	0.000193	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—multiple sclerosis	3.42e-05	0.000193	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—multiple sclerosis	3.42e-05	0.000193	CcSEcCtD
Thalidomide—Vomiting—Prednisone—multiple sclerosis	3.29e-05	0.000185	CcSEcCtD
Thalidomide—Rash—Prednisone—multiple sclerosis	3.26e-05	0.000184	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—multiple sclerosis	3.26e-05	0.000184	CcSEcCtD
Thalidomide—Headache—Prednisone—multiple sclerosis	3.24e-05	0.000183	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—multiple sclerosis	3.19e-05	0.00018	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—multiple sclerosis	3.1e-05	0.000175	CcSEcCtD
Thalidomide—Nausea—Prednisone—multiple sclerosis	3.07e-05	0.000173	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—multiple sclerosis	3.06e-05	0.000172	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—multiple sclerosis	2.96e-05	0.000167	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—multiple sclerosis	2.86e-05	0.000161	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—multiple sclerosis	2.75e-05	0.000155	CcSEcCtD
Thalidomide—Rash—Methotrexate—multiple sclerosis	2.73e-05	0.000154	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—multiple sclerosis	2.72e-05	0.000154	CcSEcCtD
Thalidomide—Headache—Methotrexate—multiple sclerosis	2.71e-05	0.000153	CcSEcCtD
Thalidomide—Nausea—Methotrexate—multiple sclerosis	2.57e-05	0.000145	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—MAPK1—multiple sclerosis	1.92e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SRM—multiple sclerosis	1.89e-05	0.000127	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	1.88e-05	0.000127	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	1.88e-05	0.000126	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD80—multiple sclerosis	1.86e-05	0.000125	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	1.84e-05	0.000124	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP24A1—multiple sclerosis	1.83e-05	0.000123	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP27B1—multiple sclerosis	1.83e-05	0.000123	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—multiple sclerosis	1.83e-05	0.000123	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—MAPK1—multiple sclerosis	1.83e-05	0.000123	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	1.82e-05	0.000123	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—VCAM1—multiple sclerosis	1.81e-05	0.000122	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DQA1—multiple sclerosis	1.81e-05	0.000122	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.79e-05	0.000121	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	1.79e-05	0.00012	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	1.75e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	1.75e-05	0.000118	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—RRM1—multiple sclerosis	1.75e-05	0.000118	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—TYK2—multiple sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP27B1—multiple sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP24A1—multiple sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—VCAM1—multiple sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SRM—multiple sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQA1—multiple sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DQB1—multiple sclerosis	1.69e-05	0.000114	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPC5—multiple sclerosis	1.67e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—TYK2—multiple sclerosis	1.64e-05	0.00011	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD86—multiple sclerosis	1.63e-05	0.00011	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	1.62e-05	0.000109	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	1.62e-05	0.000109	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQB1—multiple sclerosis	1.61e-05	0.000108	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL3—multiple sclerosis	1.6e-05	0.000108	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—multiple sclerosis	1.6e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	1.59e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.59e-05	0.000107	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—multiple sclerosis	1.58e-05	0.000107	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—multiple sclerosis	1.58e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPC5—multiple sclerosis	1.58e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPC5—multiple sclerosis	1.57e-05	0.000106	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—multiple sclerosis	1.56e-05	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD86—multiple sclerosis	1.55e-05	0.000104	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTGER4—multiple sclerosis	1.54e-05	0.000104	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—multiple sclerosis	1.54e-05	0.000104	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL3—multiple sclerosis	1.52e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-B—multiple sclerosis	1.52e-05	0.000102	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PGR—multiple sclerosis	1.52e-05	0.000102	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—multiple sclerosis	1.52e-05	0.000102	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—multiple sclerosis	1.5e-05	0.000101	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—multiple sclerosis	1.5e-05	0.000101	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—multiple sclerosis	1.5e-05	0.000101	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCR3—multiple sclerosis	1.49e-05	0.0001	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TYK2—multiple sclerosis	1.49e-05	0.0001	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPC5—multiple sclerosis	1.49e-05	0.0001	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—multiple sclerosis	1.48e-05	9.97e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—multiple sclerosis	1.48e-05	9.96e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CD28—multiple sclerosis	1.48e-05	9.95e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SRM—multiple sclerosis	1.47e-05	9.9e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTGER4—multiple sclerosis	1.46e-05	9.87e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR2—multiple sclerosis	1.45e-05	9.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-B—multiple sclerosis	1.44e-05	9.72e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PGR—multiple sclerosis	1.44e-05	9.72e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD86—multiple sclerosis	1.43e-05	9.62e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2RA—multiple sclerosis	1.42e-05	9.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—multiple sclerosis	1.42e-05	9.57e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCR3—multiple sclerosis	1.41e-05	9.53e-05	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	1.41e-05	9.53e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-A—multiple sclerosis	1.41e-05	9.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—multiple sclerosis	1.4e-05	9.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CD28—multiple sclerosis	1.4e-05	9.44e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—RRM1—multiple sclerosis	1.39e-05	9.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR2—multiple sclerosis	1.38e-05	9.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—STAT3—multiple sclerosis	1.37e-05	9.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—POMC—multiple sclerosis	1.36e-05	9.18e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.36e-05	9.13e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2RA—multiple sclerosis	1.35e-05	9.11e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CNR1—multiple sclerosis	1.34e-05	9.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-A—multiple sclerosis	1.34e-05	9.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	1.33e-05	8.96e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	1.33e-05	8.96e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—RRM1—multiple sclerosis	1.31e-05	8.8e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.3e-05	8.78e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RPL5—multiple sclerosis	1.3e-05	8.76e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.3e-05	8.75e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR4—multiple sclerosis	1.29e-05	8.68e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DRB1—multiple sclerosis	1.29e-05	8.67e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.28e-05	8.62e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.28e-05	8.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CNR1—multiple sclerosis	1.27e-05	8.56e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—multiple sclerosis	1.27e-05	8.54e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CCR5—multiple sclerosis	1.27e-05	8.53e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.25e-05	8.44e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SLC11A1—multiple sclerosis	1.24e-05	8.39e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MAPK1—multiple sclerosis	1.24e-05	8.37e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ICAM1—multiple sclerosis	1.24e-05	8.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HLA-A—multiple sclerosis	1.23e-05	8.32e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—RRM1—multiple sclerosis	1.23e-05	8.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR4—multiple sclerosis	1.22e-05	8.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—multiple sclerosis	1.22e-05	8.23e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPC5—multiple sclerosis	1.22e-05	8.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	1.21e-05	8.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	1.21e-05	8.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL10—multiple sclerosis	1.21e-05	8.12e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.19e-05	8.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD80—multiple sclerosis	1.19e-05	8.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.18e-05	7.98e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—multiple sclerosis	1.18e-05	7.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ICAM1—multiple sclerosis	1.17e-05	7.9e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—multiple sclerosis	1.17e-05	7.89e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.16e-05	7.85e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOE—multiple sclerosis	1.15e-05	7.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL10—multiple sclerosis	1.14e-05	7.71e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD80—multiple sclerosis	1.13e-05	7.6e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.11e-05	7.47e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MAPK1—multiple sclerosis	1.1e-05	7.39e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.08e-05	7.25e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.06e-05	7.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CD86—multiple sclerosis	1.05e-05	7.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD80—multiple sclerosis	1.04e-05	7.02e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—STAT3—multiple sclerosis	1.04e-05	7.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MAPK1—multiple sclerosis	1.04e-05	7.01e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL5—multiple sclerosis	1.04e-05	6.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.04e-05	6.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.04e-05	6.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.01e-05	6.82e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.01e-05	6.79e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TYK2—multiple sclerosis	1e-05	6.76e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—BCHE—multiple sclerosis	1e-05	6.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CD86—multiple sclerosis	1e-05	6.74e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD28—multiple sclerosis	9.94e-06	6.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL5—multiple sclerosis	9.84e-06	6.63e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—multiple sclerosis	9.65e-06	6.5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SPP1—multiple sclerosis	9.61e-06	6.47e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.55e-06	6.43e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—multiple sclerosis	9.55e-06	6.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TYK2—multiple sclerosis	9.53e-06	6.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPC5—multiple sclerosis	9.47e-06	6.38e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MAPK1—multiple sclerosis	9.46e-06	6.38e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—multiple sclerosis	9.4e-06	6.33e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR5—multiple sclerosis	9.35e-06	6.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.24e-06	6.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2RA—multiple sclerosis	9.21e-06	6.21e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RRM1—multiple sclerosis	9.18e-06	6.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SPP1—multiple sclerosis	9.12e-06	6.14e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—multiple sclerosis	9.08e-06	6.12e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—multiple sclerosis	8.92e-06	6.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR5—multiple sclerosis	8.87e-06	5.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TYK2—multiple sclerosis	8.79e-06	5.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2RA—multiple sclerosis	8.74e-06	5.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—multiple sclerosis	8.61e-06	5.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—multiple sclerosis	8.5e-06	5.73e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—multiple sclerosis	8.43e-06	5.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.43e-06	5.68e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—multiple sclerosis	8.38e-06	5.65e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—multiple sclerosis	8.35e-06	5.63e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.2e-06	5.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—multiple sclerosis	8.07e-06	5.44e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—multiple sclerosis	8e-06	5.39e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—BCHE—multiple sclerosis	7.97e-06	5.37e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—multiple sclerosis	7.96e-06	5.36e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—multiple sclerosis	7.95e-06	5.36e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—multiple sclerosis	7.93e-06	5.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RRM1—multiple sclerosis	7.85e-06	5.29e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.81e-06	5.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CD80—multiple sclerosis	7.69e-06	5.18e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—BCHE—multiple sclerosis	7.5e-06	5.05e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—BCHE—multiple sclerosis	7.48e-06	5.04e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.48e-06	5.04e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—multiple sclerosis	7.31e-06	4.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CD80—multiple sclerosis	7.3e-06	4.92e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—multiple sclerosis	7.27e-06	4.9e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—multiple sclerosis	7.15e-06	4.82e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.13e-06	4.8e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD86—multiple sclerosis	7.09e-06	4.78e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—BCHE—multiple sclerosis	7.07e-06	4.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STAT3—multiple sclerosis	7.03e-06	4.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—multiple sclerosis	6.93e-06	4.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—multiple sclerosis	6.78e-06	4.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.71e-06	4.52e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—multiple sclerosis	6.67e-06	4.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TYK2—multiple sclerosis	6.49e-06	4.37e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK1—multiple sclerosis	6.39e-06	4.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCR5—multiple sclerosis	6.29e-06	4.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TYK2—multiple sclerosis	6.16e-06	4.15e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—multiple sclerosis	6.16e-06	4.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HLA-A—multiple sclerosis	6.13e-06	4.13e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.12e-06	4.12e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.12e-06	4.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.09e-06	4.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK1—multiple sclerosis	6.06e-06	4.09e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—multiple sclerosis	6.04e-06	4.07e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—BCHE—multiple sclerosis	5.79e-06	3.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—multiple sclerosis	5.72e-06	3.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—multiple sclerosis	5.72e-06	3.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—multiple sclerosis	5.71e-06	3.85e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK1—multiple sclerosis	5.6e-06	3.77e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.58e-06	3.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—multiple sclerosis	5.4e-06	3.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—BCHE—multiple sclerosis	5.28e-06	3.55e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.23e-06	3.52e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—multiple sclerosis	5.19e-06	3.49e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD80—multiple sclerosis	5.17e-06	3.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—multiple sclerosis	5.12e-06	3.45e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—multiple sclerosis	5.11e-06	3.44e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—multiple sclerosis	4.91e-06	3.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—multiple sclerosis	4.85e-06	3.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—multiple sclerosis	4.79e-06	3.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.77e-06	3.21e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—multiple sclerosis	4.73e-06	3.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—multiple sclerosis	4.66e-06	3.14e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—multiple sclerosis	4.54e-06	3.06e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—multiple sclerosis	4.51e-06	3.04e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BCHE—multiple sclerosis	4.51e-06	3.04e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—multiple sclerosis	4.5e-06	3.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TYK2—multiple sclerosis	4.37e-06	2.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—multiple sclerosis	4.31e-06	2.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—multiple sclerosis	4.3e-06	2.9e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—multiple sclerosis	4.25e-06	2.87e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—multiple sclerosis	4.22e-06	2.85e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—multiple sclerosis	4.21e-06	2.84e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK1—multiple sclerosis	4.13e-06	2.78e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—multiple sclerosis	4.12e-06	2.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—multiple sclerosis	4.01e-06	2.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—multiple sclerosis	4e-06	2.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—multiple sclerosis	3.95e-06	2.66e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK1—multiple sclerosis	3.92e-06	2.64e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—multiple sclerosis	3.88e-06	2.61e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—multiple sclerosis	3.87e-06	2.61e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—multiple sclerosis	3.75e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—multiple sclerosis	3.65e-06	2.46e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—multiple sclerosis	3.53e-06	2.38e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—multiple sclerosis	3.53e-06	2.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—multiple sclerosis	3.48e-06	2.35e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—multiple sclerosis	3.33e-06	2.24e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—multiple sclerosis	3.17e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—multiple sclerosis	3.17e-06	2.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—multiple sclerosis	3.06e-06	2.06e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—multiple sclerosis	3.01e-06	2.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—multiple sclerosis	2.99e-06	2.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—multiple sclerosis	2.84e-06	1.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—multiple sclerosis	2.83e-06	1.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK1—multiple sclerosis	2.78e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—multiple sclerosis	2.73e-06	1.84e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—multiple sclerosis	2.73e-06	1.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—multiple sclerosis	2.71e-06	1.83e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—multiple sclerosis	2.49e-06	1.67e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—multiple sclerosis	2.33e-06	1.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—multiple sclerosis	2.14e-06	1.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—multiple sclerosis	2.12e-06	1.43e-05	CbGpPWpGaD
